for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Syros Pharmaceuticals Inc

SYRS.OQ

Latest Trade

7.92USD

Change

0.06(+0.76%)

Volume

180,799

Today's Range

7.73

 - 

7.99

52 Week Range

4.29

 - 

14.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.86
Open
7.86
Volume
180,799
3M AVG Volume
9.93
Today's High
7.99
Today's Low
7.73
52 Week High
14.69
52 Week Low
4.29
Shares Out (MIL)
45.81
Market Cap (MIL)
361.68
Forward P/E
-4.93
Dividend (Yield %)
--

Latest Developments

More

Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results And Highlights Key Accomplishments And Upcoming Milestones

Syros Presents Initial Data From Phase 1 Clinical Trial Of SY-5609 At Eortc-Nci-Aacr Meeting

Syros Pharmaceuticals Q2 Revenue $3.2 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.

Industry

Biotechnology & Drugs

Contact Info

35 CAMBRIDGE PARK DRIVE

CAMBRIDGE, MA

02140

United States

+1.617.7441340

https://syros.com/

Executive Leadership

Peter Wirth

Independent Chairman of the Board

Nancy A. Simonian

President, Chief Executive Officer, Director

Joseph J. Ferra

Chief Financial Officer

Eric R. Olson

Chief Scientific Officer

Gerald E. Quirk

Chief Legal & Administrative Officer

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-2.130

2018

-1.910

2019

-1.880

2020(E)

-1.615
Price To Earnings (TTM)
--
Price To Sales (TTM)
36.52
Price To Book (MRQ)
7.87
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
44.41
LT Debt To Equity (MRQ)
43.85
Return on Investment (TTM)
-65.01
Return on Equity (TTM)
-53.14

Latest News

Latest News

BRIEF-Syros Pharmaceuticals Says Entered Into A Sales Agreement With Cowen & Company, Dated June 12

* SYROS PHARMACEUTICALS INC - ENTERED INTO A SALES AGREEMENT WITH COWEN & COMPANY, DATED JUNE 12

BRIEF-Syros Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing

* SYROS PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING Source text for Eikon: https://bit.ly/3dXPST3 Further company coverage:

BRIEF-Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program

* SYROS PHARMACEUTICALS INC - PRESENTS NEW PRECLINICAL DATA HIGHLIGHTING THERAPEUTIC POTENTIAL OF SY-5609 IN COLORECTAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Syros Pharmaceuticals Q1 Loss Per Share $0.39

* SYROS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS AND ANTICIPATED MILESTONES

BRIEF-Syros Pharma To Sell Shares Of Co's Common Stock Of Up To $50 Mln

* SYROS PHARMACEUTICALS - TO OFFER AND SELL SHARES OF CO'S COMMON STOCK OF UP TO $50 MILLION THROUGH COWEN, ACTING AS CO'S AGENT - SEC FILING Source text: (http://bit.ly/2Q9zw07) Further company coverage:

BRIEF-Syros Reports Q4 Loss Per Share $0.46

* SYROS REPORTS FOURTH QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS KEY ACCOMPLISHMENTS AND UPCOMING MILESTONES

BRIEF-Syros Announces $60 Million Loan Facility With Oxford Finance Llc

* SYROS ANNOUNCES $60 MILLION LOAN FACILITY WITH OXFORD FINANCE LLC

BRIEF-Syros Pharmaceuticals Reports Q4 Loss Per Share $0.58

* SYROS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS AND ANTICIPATED MILESTONES

BRIEF-Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte

* SYROS PHARMACEUTICALS - ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING

BRIEF-Syros Prices Public Offering Of 4.19 Mln Common Shares At $9.55/Share

* SYROS ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Syros Announces Proposed Offering Of Common Stock

* SYROS PHARMACEUTICALS INC - OFFERING TO SELL $40.0 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement

* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT

BRIEF-Syros Announces 2018 Strategic Priorities And Expected Milestones

* SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES

BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425

* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up